A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users

被引:69
作者
Macalino, Grace E.
Hogan, Joseph W.
Mitty, Jennifer A.
Bazerman, Lauri B.
DeLong, Alison K.
Loewenthal, Helen
Caliendo, Angela M.
Flanigan, Timothy P.
机构
[1] Arthur Ashe Inst Urban Hlth, Brooklyn, NY 11203 USA
[2] Brown Univ, Ctr Stat Sci, Providence, RI 02912 USA
[3] Brown Univ, Miriam Hosp, Warren Alpert Med Sch, Providence, RI 02912 USA
[4] Emory Univ, Sch Med, Atlanta, GA 30322 USA
关键词
AIDS; HIV; HAART; viral load; substance users; modified directly observed therapy (MDOT); directly observed therapy; outreach; heroin; CD4; ADMINISTERED ANTIRETROVIRAL THERAPY; DRUG-USERS; MORTALITY; IMPACT; RESISTANCE; FAILURE; COHORT; ADULTS;
D O I
10.1097/QAD.0b013e32811ebf68
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Adherence interventions for HAART can impact challenging populations, such as active substance users. Community-based modified directly observed therapy (MDOT) is a promising approach that needs to be critically evaluated. Methods: This study was a randomized clinical trial. HIV seropositive substance users were randomized to either standard of care (SOC) or MDOT, stratified by HAART experience. All participants were placed on a once-daily regimen and were met by an outreach worker for all 7 days during the first 3 months. We used an intent-to-treat analysis to evaluate differences in viral load suppression [> 2 log drop in plasma viral load (PVL) or PVL < 50] and changes in PVL and CD4 cell count from baseline to 3 months. Results: A total of 87 participants were enrolled (43 in SOC, 44 in MDOT), Using repeated measures logistic regression, MDOT participants were more likely to achieve PVL suppression (odds ratio, 2.16; 95% confidence interval, 1.0-4.7), driven primarily by those HAART experienced (odds ratio, 2.88; 95% confidence interval, 1.2-7.0). A significant treatment effect was also found in CD4 cell count change (P < 0.05). No differences were found by arm in undetectable PVL. Conclusion: This study provides evidence that MDOT is an effective strategy to reduce viral load and increase CD4 cell counts in HAART experienced substance users. MDOT should be included in the spectrum of options to enhance adherence in this population. (c) 2007 Lippincott Williams & Wilkins.
引用
收藏
页码:1473 / 1477
页数:5
相关论文
共 26 条
  • [1] Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: Implications for program replication
    Altice, FL
    Mezger, JA
    Hodges, J
    Bruce, RD
    Marinovich, A
    Walton, M
    Springer, SA
    Friedland, GH
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 : S376 - S387
  • [2] Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users
    Arnsten, JH
    Demas, PA
    Grant, RW
    Gourevitch, MN
    Farzodegan, H
    Howard, AA
    Schoenboum, EE
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2002, 17 (05) : 377 - 381
  • [3] Nonadherence among HIV-Infected injecting drug users: The impact of social instability
    Bouhnik, AD
    Chesney, M
    Carrieri, P
    Gallais, H
    Moreau, J
    Moatti, JP
    Obadia, Y
    Spire, B
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 : S149 - S153
  • [4] Antiretroviral therapy in adults - Updated recommendations of the International AIDS Society-USA Panel
    Carpenter, CCJ
    Cooper, DA
    Fischl, MA
    Gatell, JM
    Gazzard, BG
    Hammer, SM
    Hirsch, MS
    Jacobsen, DM
    Katzenstein, DA
    Montaner, JSG
    Richman, DD
    Saag, MS
    Schechter, M
    Schooley, RT
    Vella, S
    Yeni, PG
    Volberding, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (03): : 381 - 390
  • [5] Failure to maintain adherence to HAART in a cohort of french HIV-positive injecting drug users
    Carrieri, MP
    Chesney, MA
    Spire, B
    Loundou, A
    Sobel, A
    Lepeu, G
    Moatti, JP
    [J]. INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE, 2003, 10 (01) : 1 - 14
  • [6] Substance abuse and psychiatric disorders in HIV-positive patients - Epidemiology and impact on antiretroviral therapy
    Chander, Geetanjali
    Himelhoch, Seth
    Moore, Richard D.
    [J]. DRUGS, 2006, 66 (06) : 769 - 789
  • [7] The population effectiveness of highly active antiretroviral therapy: are good drugs good enough?
    Giordano T.P.
    Suarez-Almazor M.E.
    Grimes R.M.
    [J]. Current HIV/AIDS Reports, 2005, 2 (4) : 177 - 183
  • [8] The social realities of adherence to protease inhibitor regimens: Substance use, health care and psychological states
    Halkitis, PN
    Kutnick, AH
    Slater, S
    [J]. JOURNAL OF HEALTH PSYCHOLOGY, 2005, 10 (04) : 545 - 558
  • [9] Determinants of HAART discontinuation among injection drug users
    Kerr, T
    Marshall, A
    Walsh, J
    Palepu, A
    Tyndall, M
    Montaner, J
    Hogg, R
    Wood, E
    [J]. AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2005, 17 (05): : 539 - 549
  • [10] Measuring adherence to highly active antiretroviral therapy: implications for research and practice.
    Kerr T.
    Walsh J.
    Lloyd-Smith E.
    Wood E.
    [J]. Current HIV/AIDS Reports, 2005, 2 (4) : 200 - 205